DIVISLAB9,415.00

Divi's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersLAURUSLABSCOHANCEGLANDTORNTPHARMZYDUSLIFEMAXHEALTHDRREDDYCIPLAMcap ₹2.49L Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
DIVISLAB
FY26
LAURUSLABS
FY26
COHANCE
FY26
GLAND
FY26
Peer
Median
Valuation — at last close
P/E97.31×117.94×94.67×47.31×94.67× +3%
P/B14.89×19.31×4.21×4.69×4.69× +217%
EV/EBITDA72.47×60.27×39.44×27.91×39.44× +84%
Market Cap₹2.49L Cr₹1.05L Cr₹16,987 Cr₹48,604 Cr₹48,604 Cr +413%
Growth
Revenue CAGR 3Y10.78%4.09%19.17%21.06%19.17% -44%
Revenue CAGR 5Y8.67%7.19%17.57%13.18%13.18% -34%
Net Income CAGR 3Y12.09%3.91%-28.53%9.57%3.91% +209%
Revenue YoY (latest Q)27.80%29.10%-23.13%19.57%19.57% +42%
Net Income YoY (latest Q)65.50%123.94%-197.39%47.09%47.09% +39%
Profitability
EBITDA Margin32.59%26.09%18.82%25.34%25.34% +29%
Net Income Margin24.32%13.07%6.62%15.98%13.07% +86%
Return on Common Equity15.32%16.36%4.44%9.92%9.92% +54%
Return on Capital Employed16.55%18.87%4.71%11.06%11.06% +50%
Return on Assets12.82%8.47%2.62%8.21%8.21% +56%
Credit & Quality
Total Debt/Equity0.00×0.44×0.04×0.02×0.04× -100%
Interest Coverage129.48×7.60×6.44×36.24×7.60× +1604%
Scale — latest FY
Revenue / Total Income₹10,560 Cr₹6,813 Cr₹2,269 Cr₹6,431 Cr₹6,431 Cr +64%
Net Income₹2,568 Cr₹890 Cr₹150 Cr₹1,027 Cr₹890 Cr +188%
Total Assets₹20,033 Cr₹10,511 Cr₹5,730 Cr₹12,511 Cr₹10,511 Cr +91%
EPS₹96.75₹16.47₹4.69₹62.35₹16.47 +487%
Book Value per Share₹632.49₹100.61₹105.43₹628.67₹105.43 +500%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.